Previous 10 | Next 10 |
CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September: Citi’s 15 th Annual BioP...
Image source: The Motley Fool. Amicus Therapeutics Inc (NASDAQ: FOLD) Q2 2020 Earnings Call Aug 10, 2020 , 8:30 a.m. ET Operator Continue reading
Amicus Therapeutics, Inc. (FOLD) Q2 2020 Earnings Conference Call August 10, 2020 08:30 AM ET Company Participants Andrew Faughnan - Director of Investor Relations John Crowley - Chairman & Chief Executive Officer Bradley Campbell - President & Chief Operating Officer D...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Amicus Therapeutics (NASDAQ: FOLD ) : Q2 GAAP EPS of -$0.20 beats by $0.07 . More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of $250M-$260M AT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on Schedule Advancing Industry-Leading Rare Disease Gene Therapy Portfolio Path to...
CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T. A live aud...
CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2020. The...
Applied DNA reports positive preclinical results for COVID-19 vaccine Applied DNA Sciences Inc. ( APDN ) announced that its COVID-19 vaccine candidate has yielded robust antibody and T-cell responses even at very low doses of linear DNA. The company is collaborating with Takis Biotech for ...
Amicus Therapeutics (NASDAQ: FOLD ) inks an agreement with Hayfin Capital Management for a $400M credit facility at 6.5% above LIBOR subject to a 1% floor. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....